PHVS: Rega marang dodolan Pharvaris Corp
The primary driver for Pharvaris N.V. (PHVS) will be the market launch of oral treatments for hereditary angioedema. The price-to-sales multiple visualizes investor expectations, where the value represents the current metric. Profit potential is linked to replacing injections with tablets for HAE patients. Furthermore, the focus on proprietary internal development makes the company an attractive acquisition target for corporate behemoths.
Rincian metrik lan analitis perusahaan Pharvaris Corp (PHVS)
- rega saham lan target rega konsensus:
- informasi kapitalisasi pasar:
- data nilai buku modal saham:
- indikator beban kredit lan likuiditas emiten:
Total Utang marang Modal Pharvaris N.V.|PHVS - Utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal Pharvaris Pharma|PHVS - Gunggung utang perusahaan|Rasio utang marang kapitalisasi buku Pharvaris Corp|PHVS - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Pharvaris|Rasio jangkoan perantara pharvaris.com
- indikator bathi lan kelipatan valuasi:
PHVS - Bathi resik|Prakiraan bathi perusahaan Pharvaris N.V.|PHVS - Rasio rega marang bathi|Kapitalisasi marang proyeksi bathi Pharvaris NV|PHVS - Pangali rega marang bathi tumrap wutah|Nilai bisnis marang bathi operasional sadurunge panyusutan Pharvaris Corp|PHVS - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi saben saham sajrone 12 wulan pungkasan Pharvaris|PHVS - Bathi resik saben saham sajrone 12 wulan pungkasan|Owah-owahan bathi resik saben saham taun-ka-taun sajrone rolas wulan pungkasan pharvaris.com|PHVS - Wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Pharvaris N.V.
- rincian pendapatan lan dodolan emiten:
Ringkesan analitik perusahaan:pharvaris.com PHVS
The implementation of AI and automated compound synthesis systems at Pharvaris N.V. (PHVS) is accelerating preclinical testing, directly impacting the potential of future cash flows. By analyzing the historical P/S chart, an investor assesses the market value of the business through the ratio of market capitalization to total revenue, where a stable trend confirms sales resilience, while sharp deviations signal overvaluation or hidden reporting risks.
Perusahaan pesaing
argenx.com - Rasio kapitalisasi marang pendapatan|Multiplikator P/S BNTX (BioNTech)|Abivax Pharma (ABVX) - Rega marang dodolan|ADMA - Rasio rega marang pendapatan|Rasio rega marang dodolan PTGX|IMVT: Multiplikator P/S|kiniksa.com - Rasio kapitalisasi pasar marang pendapatan|GRFS (Grifols) - Multiplikator P/S|Multiplikator P/S Adaptive Biotech|Rasio rega marang pendapatan Celldex (CLDX)|AUPH (Aurinia Corp) - Rasio kapitalisasi pasar marang pendapatan|BioCryst - Kapitalisasi marang pendapatan|veratx.com - Rasio rega marang pendapatan|Dianthus Therapeutics, Inc. - Multiplikator P/S|ABCL - Multiplikator P/S|Tourmaline Corp (TRML) - Rasio rega marang pendapatan|Precigen Corp - Rasio kapitalisasi pasar marang pendapatan|PHAR (Pharming Group N.V.) - Multiplikator P/S|nektar.com (NKTR) - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Upstream Bio (UPB)|Koefisien rega marang pendapatan Zenas Bio|Immunome Corp - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan GOSS|KALV - Rasio rega marang pendapatan|SEPN (septerna.com) - Rasio kapitalisasi marang pendapatan|PVLA (Pieris Pharmaceuticals, Inc.) - Kapitalisasi marang pendapatan|SVRA - Koefisien rega marang pendapatan|Kapitalisasi marang pendapatan RIGL|Rasio rega marang pendapatan ANAB|Kapitalisasi marang pendapatan ATXS (Astria Therapeutics)|Koefisien rega marang pendapatan engene.com|Rasio rega marang pendapatan RAPT Therapeutics RAPT|JBIO (Aerovate Therapeutics, Inc.) - Rasio rega marang dodolan|Aclaris - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan KYTX (Kyverna Therapeutics, Inc)|TLSA (Tiziana Life Sciences) - Kapitalisasi marang pendapatan|CABA (cabalettabio.com) - Rasio rega marang pendapatan|Rasio rega marang pendapatan Ventyx Biosciences, Inc.|Theratechnologies, Inc. (THTX) - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Avalo Therapeutics Inc. (AVTX)|ELDN: Rasio rega marang dodolan|Multiplikator P/S AGEN (Agenus)|Rasio kapitalisasi pasar marang pendapatan CLYM|Zura Bio - Multiplikator P/S|ATYR - Multiplikator P/S|adagene.com (ADAG) - Rasio rega marang pendapatan|Ikena Oncology - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Shattuck Labs Inc|Kapitalisasi marang pendapatan Equillium Bio (EQ)|Multiplikator P/S CNTB|Multiplikator P/S immunic-therapeutics.com (IMUX)|Atara Bio - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan IFRX|X4 Pharmaceuticals - Multiplikator P/S|Koefisien rega marang pendapatan Adicet Bio ACET|celularity.com (CELU) - Rasio rega marang pendapatan|Kapitalisasi marang pendapatan INmune Bio Inc|Rasio rega marang pendapatan Barinthus Bio|Kapitalisasi marang pendapatan Kezar Life Sciences Inc (KZR)|Kapitalisasi marang pendapatan SABS (SAB Biotherapeutics)|Multiplikator P/S akaritx.com (AKTX)|Rasio rega marang pendapatan Enlivex Therapeutics Ltd. ENLV|QTTB: Rasio kapitalisasi marang pendapatan|GeoVax Labs Inc - Multiplikator P/S|Rega marang dodolan Edesa Biotech Corp|iBio, Inc. (IBIO) - Rasio rega marang pendapatan|Rasio rega marang dodolan CARM (Carisma Therapeutics Inc.)|XTLB (XTL Biopharmaceuticals Ltd.) - Multiplikator P/S|BOLT: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S HCWB|Multiplikator P/S aptevotherapeutics.com (APVO)|Rasio rega marang pendapatan AIM ImmunoTech Inc. AIM|Rasio kapitalisasi pasar marang pendapatan ADTX|GRI: Kapitalisasi marang pendapatan|XRTX: Rasio rega marang pendapatan|HIND: Multiplikator P/S|Revelation Biosciences Corp (REVB) - Multiplikator P/S|Rasio rega marang pendapatan Indaptus Therapeutics|SCNI: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S CALI|Koefisien rega marang pendapatan affimed.com|Rasio rega marang pendapatan Allakos ALLK|Koefisien rega marang pendapatan HOOKIPA Pharma, Inc. (HOOK)|IGMS: Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan ITOS (iteostherapeutics.com)|Ocean Biomedical (OCEA) - Rasio rega marang pendapatan|Rasio kapitalisasi marang pendapatan TCBP|Kapitalisasi marang pendapatan THRD
